Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$19.17
-0.35 (-1.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-256.5M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.2B
P/E
1917.0x
↑EV/EBITDA
N/A
•ROE
-30.6%
↓Gross Margin
33.2%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.3%
FCF CAGR
—
FCF margin
-207.8%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $123.4M · net income $-268.1M · FCF $-256.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $123.4M | $123.4M | $129.5M | $114.2M | $84.7M |
| Net Income | $-268.1M | $-268.1M | $-201.4M | $-329.0M | $-356.8M |
| EBITDA | $-215.9M | $-215.9M | $-149.3M | $-275.1M | $-300.7M |
| EPS | -0.72 | -0.72 | -0.54 | -0.88 | -0.98 |
| Gross Margin | 33.2% | 33.2% | 33.9% | 29.0% | 18.6% |
| Operating Margin | -195.3% | -195.3% | -178.9% | -289.3% | -442.4% |
| Net Margin | -217.2% | -217.2% | -155.5% | -287.9% | -421.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.37 | 0.29 | 0.17 |
| Current Ratio | 3.54 | 3.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-256.5M | $-256.5M | $-191.1M | $-396.5M | $-429.4M |
| Returns | |||||
| ROE | -30.6% | -30.6% | -17.6% | -24.5% | -21.3% |
| Valuation | |||||
| P/E | 1917.00 | 1917.00 | — | — | — |
| P/B | 8.14 | 8.14 | 3.05 | 2.68 | 3.68 |
| Growth & Yield | |||||
| Revenue Growth | -4.7% | -4.7% | 13.3% | 34.8% | — |
| EPS Growth | -33.3% | -33.3% | 38.6% | 10.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+118.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.54 → -0.72
Residual
+118.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.